Docs offer varied cures for ailing health care system
Indianapolis physicians are mixed on the merits of a government-run, "public" health insurance plan. How reforms
might affect their pay is another major concern.
Indianapolis physicians are mixed on the merits of a government-run, "public" health insurance plan. How reforms
might affect their pay is another major concern.
With the Obama administration backing away from a government-run, "public" plan, the insurance
industry faces a much smaller threat in the form of privately run insurance co-ops.
Indianapolis-based startup My Health Care Manager has signed an agreement with Indianapolis-based
WellPoint Inc. that will eventually put My Health Care Manager’s elder care service in front of the health insurer’s
thousands of employer clients and their workers around the country.
There was a time, of course, when journalists had the time, space, resources and respect to sort things out for us.
Companies are helping workers age 65 and above decide whether to forgo their company health insurance and shift to Medicare.
Medicare is becoming more attractive as costs of company policies rise.
Indianapolis-based Monarch Beverage is among hundreds of central Indiana companies that
have introduced wellness programs to counteract the rising costs of health insurance and Worker’s Compensation.
Safeco is leaving a five-building complex on North Meridian Street, and Eli Lilly and Co. has offered for lease its entire
four-building Faris campus.
In almost every place that two or more Americans gather, health care is debated. Because the bills before Congress are
inaccessible, the debate has shifted instead to principles such as the role of government and individual freedoms. I think this a healthy thing.
Lots of people are
without health insurance, but that doesn’t necessarily mean they go without health care. Others have insurance that
doesn’t cover their needs. Either they don’t get the care or they go broke in the process.
In the eyes of Scott Law, Congress is heading in exactly the wrong direction on health care reform.
But the
CEO of Zotec Partners predicts a big bump in sales for his physician-billing management company if current reform proposals
become law.
Conseco Inc. recorded profit at the high-end of its preliminary
estimates, the company announced today.
The CEO of Indianapolis-based Arcadia Resources said the environment is perfect for his company’s fast-growing DailyMed
service.
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
Baldwin & Lyons Inc. said today that its profit last quarter was the second-highest in company
history, as investment gains from recovering equity markets helped boost performance.
As concern grows among medical providers that health care reform augurs lower payments, St. Francis
Hospital & Health Centers has agreed to absorb a large group of cardiologists that bring lucrative heart patients to its
facilities.
The Indianapolis Colts have become one of the first National Football League teams to sell a corporate sponsorship patch
on players’ practice jersey.
Local businessman J.B. Carlson contends the $15 million life insurance policy he took out on Stephen Hilbert’s mother-in-law
was legitimate, because she served on his firm’s board and was a key decision-maker. The mother-in-law, Germaine
“Suzy” Tomlinson, died at age 74 last September—just 32 months after the policy was issued.
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Two Indianapolis benefits consulting firms have finalized their merger, the companies announced this morning. Terms of the
deal between Benefit Associates Inc. and Benefit Consultants Inc., in the works since March, were not disclosed.
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.